Hypermobile Ehlers-Danlos syndrome (hEDS) is often misunderstood as “just being flexible.” In reality, it is a complex, multisystem connective tissue disorder that affects far more than joints. For many patients, hEDS exists alongside a constellation of comorbid conditions—neurological, immunological, autonomic, and gynecological—that shape daily life in profound ways.

Understanding these overlaps is essential not only for medical care, but also for helping patients develop meaningful, sustainable strategies for living with chronic pain and disability.

---

What is Hypermobile Ehlers-Danlos Syndrome?

hEDS is one of the most common forms of Ehlers-Danlos syndrome, characterized by joint hypermobility, chronic musculoskeletal pain, joint instability, and soft or fragile connective tissue. However, research increasingly shows that hEDS is a systemic condition, not just a musculoskeletal one. Patients frequently experience fatigue, gastrointestinal dysfunction, headaches, and cognitive difficulties (“brain fog”), alongside chronic pain. 

​

One of the defining features of hEDS is its high rate of comorbid conditions. Rather than existing in isolation, hEDS often overlaps with several other syndromes that may share underlying mechanisms such as connective tissue fragility, immune dysregulation, and nervous system dysfunction.

 

Dysautonomia (POTS, Innapropriate Sinus Tachycardia, Autonomic Dysfunction, Vasovagal Syncope)

* Over half of patients in some studies report a POTS diagnosis (Hutchinson, et.al., 2025)
* Symptoms include dizziness, tachycardia, fatigue, and exercise intolerance

Autonomic dysfunction in hEDS can be severe, with symptom burden reported as worse than several other chronic diseases.

​

Mast Cell Activation Syndrome (MCAS)

MCAS involves inappropriate activation of mast cells, leading to:

* Allergic-type reactions (hives, flushing)
* Gastrointestinal symptoms
* Cardiovascular instability
* Neuropsychiatric symptoms

Around one-third to 40% of hEDS patients report MCAS in research cohorts. (Hutchinson et. al., 2025). Emerging research suggests that mast cell dysfunction may also contribute to psychiatric and neurological symptoms, including anxiety and attention-related difficulties. (Weinstock, L. B., Nelson, R. M., & Blitshteyn, S. (2023).

​

ADHD and Neurodivergence

Neurodevelopmental conditions—particularly ADHD—are increasingly recognized in hEDS populations.

* Around **25% of patients** report ADHD in some studies (Darakjian et. al., 2024). 
* Neurodivergent conditions (including autism and ADHD) are specifically listed among common comorbidities in clinical overviews 

The connection may involve shared pathways such as autonomic dysregulation, sensory processing differences, and connective tissue differences affecting the nervous system.

​

PMDD and Gynecological Conditions

Hormonal and gynecological issues are frequently reported but often under-discussed:

* Dysmenorrhea, heavy bleeding, endometriosis, and pelvic pain are common 
* Many patients report symptoms consistent with Premenstrual Dysphoric Disorder (PMDD), though research is still emerging

Hormonal fluctuations may exacerbate joint instability, pain, mast cell activity, and autonomic symptoms—creating cyclical worsening of overall health.

​

The “Triad” and Beyond

A commonly discussed cluster in research and patient communities is:

* hEDS (hypermobile Ehlers Danlos Syndrome)
* Dysautonomia (POTS)
* MCAS (Mast Cell Activation Syndrome)

In one study, **25% of patients had all three simultaneously**, illustrating how deeply interconnected these systems are. (Hutchinson et. al., 2025)

Beyond this triad, patients may also experience:

* Chronic fatigue syndrome (ME/CFS)
* Migraine
* Gastrointestinal disorders (IBS, dysmotility)
* Anxiety and depression

These overlapping conditions contribute to significantly reduced quality of life. (Hutchinson et. al, 2025)

​

Traditional medical models often treat each condition separately. But for hEDS patients, this fragmented approach can fail.

Research shows that patients with overlapping comorbidities experience:

* Greater symptom burden
* Worse quality of life
* Increased disability

​

Chronic Pain, Identity, and Psychological Flexibility

Living with hEDS often means navigating:

* Unpredictable pain
* Fluctuating energy levels
* Medical gaslighting or delayed diagnosis
* Loss of previous identity or abilities

This is where psychological approaches—particularly Acceptance and Commitment Therapy (ACT)—can play a transformative role.

​

How Acceptance and Commitment Therapy (ACT) Helps

ACT is not about “accepting suffering” or giving up. Instead, it focuses on psychological flexibility—the ability to live a meaningful life even in the presence of pain.

​

1. Radical Acceptance of Reality

Radical acceptance helps patients acknowledge:

* “My pain is real”
* “My body has limits”

This reduces the constant mental struggle against symptoms, which can otherwise amplify suffering.

For Ehlers Danlos Syndrome patients, this might look like accepting that energy levels fluctuate daily or recognizing that pushing through pain may lead to flares

​

2. Values-Based Living

ACT encourages identifying core values (e.g., creativity, connection, autonomy) and finding ways to engage with them within physical limits. Example: A patient who values connection might shift from in-person socializing to virtual meetups during flares

​

3. Identifying Appropriate Accommodations

By combining acceptance with values, patients can ask:

* “What do I need to live in alignment with my values?”
* “What accommodations support—not restrict—my life?”

Examples of ACT-informed accommodations:

* Mobility aids (used proactively, not as a “last resort”)
* Flexible work schedules or remote work
* Scheduled rest periods (“pacing”)
* Sensory modifications (for ADHD or MCAS triggers)
* Hormonal tracking to anticipate PMDD-related flares

Instead of viewing accommodations as “giving up,” ACT reframes them as **tools for participation**.

​

4. Cognitive Defusion

Patients often internalize harmful thoughts:

* “I’m lazy”
* “I should be able to do more”

ACT teaches skills to observe these thoughts without believing them, reducing shame and burnout.

​

5. Pacing and Energy Management

ACT aligns well with pacing strategies:

* Balancing activity and rest
* Avoiding “boom-and-bust” cycles
* Respecting autonomic and immune limits (This is especially critical for patients with dysautonomia and ME/CFS overlap.)

​

Hypermobile Ehlers-Danlos syndrome challenges traditional boundaries between specialties—rheumatology, neurology, immunology, psychiatry, and gynecology all intersect here. But beyond the science, it calls for something deeper: A shift from “fixing” bodies to supporting people in building livable, meaningful lives within them. Acceptance and Commitment Therapy offers a framework for doing exactly that—helping patients move from survival toward agency, even in the presence of chronic pain.

---

1. Ashley A Darakjian, Mira Bhutani, DeLisa Fairweather, S Christian Kocsis, Jessica J Fliess, Sami Khatib, Gabe J Weigel, Elizabeth J McCabe, Varsini Balamurugan, Evan E Perona, Jessica M Gehin, Emily R Whelan, Angita Jain, Hanna Sledge, David O Hodge, Todd D Rozen, Francis A Farraye, Ozan Soyer, Joseph Cheung, Stephanie L Grach, David Shirey Jr., Shilpa Gajarawala, Bala Munipalli, Chrisandra L Shufelt, Dacre R T Knight, Katelyn A Bruno, Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders, Rheumatology Advances in Practice, Volume 8, Issue 4, 2024, rkae134, https://doi.org/10.1093/rap/rkae134

2. Collins Hutchinson, M. L., Liang, E., Fuster, E., & Blitshteyn, S. (2025). Autonomic symptom burden, comorbidities and quality of life in women with Hypermobility Spectrum Disorders and hypermobile Ehlers-Danlos syndrome. Autonomic neuroscience : basic & clinical, 262, 103356. https://doi.org/10.1016/j.autneu.2025.103356

3. Weinstock, L. B., Nelson, R. M., & Blitshteyn, S. (2023). Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series. Journal of personalized medicine, 13(11), 1562. https://doi.org/10.3390/jpm13111562